BindingDB logo
myBDB logout

BindingDB Data by Journal




PMIDDataArticle TitleCitationOrganizationData Download
3348895412Novel Pyrimidinones as SHP2 Antagonists for Treating Cancer.EBIACS Med Chem Lett 12: 3-4 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3348895618Novel Hexahydro-1EBIACS Med Chem Lett 12: 7-8 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3348895828Cyclin-Dependent Kinase Inhibitors in Cancer Therapeutics.EBIACS Med Chem Lett 12: 11-12 (2021)Usona Institute2D 3D TSV
3348896087Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.EBIACS Med Chem Lett 12: 24-29 (2021)Reaction Biology Corporation2D 3D TSV
3348896145Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.EBIACS Med Chem Lett 12: 30-38 (2021)Dana-Farber Cancer Institute2D 3D TSV
3348896272Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group.EBIACS Med Chem Lett 12: 39-47 (2021)Shenyang Pharmaceutical University2D 3D TSV
334889642The Bicyclic Form of EBIACS Med Chem Lett 12: 56-59 (2021)Aarhus University2D 3D TSV
3348896528Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction.EBIACS Med Chem Lett 12: 60-66 (2021)Indiana University School of Medicine2D 3D TSV
3348896747Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.EBIACS Med Chem Lett 12: 74-81 (2021)Max Planck Institute for Developmental Biology2D 3D TSV
334889681Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs.EBIACS Med Chem Lett 12: 82-87 (2021)Chinese Academy of Sciences2D 3D TSV
334889692Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3.EBIACS Med Chem Lett 12: 93-98 (2021)H3 Biomedicine2D 3D TSV
334889704Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen.EBIACS Med Chem Lett 12: 99-106 (2021)Merck & Co.2D 3D TSV
334889713Solution Conformations Shed Light on PROTAC Cell Permeability.EBIACS Med Chem Lett 12: 107-114 (2021)Uppsala University2D 3D TSV
3348897256Multiresidue Tetrapeptide Substitutions Yield a 140-fold Selective Melanocortin-3 over Melanocortin-4 Receptor Agonist.EBIACS Med Chem Lett 12: 115-120 (2021)University of Minnesota2D 3D TSV
33488974137Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3K? Inhibitors.EBIACS Med Chem Lett 12: 129-135 (2021)Vertex Pharmaceuticals Inc2D 3D TSV
3348897512Synthesis and Metabolism of BTN3A1 Ligands: Studies on Modifications of the Allylic Alcohol.EBIACS Med Chem Lett 12: 136-142 (2021)University of Iowa2D 3D TSV
33488976127Discovery of a Series of Pyrazinone ROR? Antagonists and Identification of the Clinical Candidate BI 730357.EBIACS Med Chem Lett 12: 143-154 (2021)Boehringer Ingelheim Pharmaceuticals2D 3D TSV
33488977119Discovery of PIPE-359, a Brain-Penetrant, Selective MEBIACS Med Chem Lett 12: 155-161 (2021)Pipeline Therapeutics2D 3D TSV
3348897818Structural Basis for Targeting the Folded P-Loop Conformation of c-MET.EBIACS Med Chem Lett 12: 162-167 (2021)AstraZeneca2D 3D TSV
336039576Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).EBIACS Med Chem Lett 12: 170-171 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
336039596Novel Galectin-3 Inhibitors for Treating Fibrosis.EBIACS Med Chem Lett 12: 174-175 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3360396120Sigma-1 and Sigma-2 Receptor Modulators as Potential Therapeutics for Alzheimer's Disease.EBIACS Med Chem Lett 12: 178-179 (2021)Usona Institute2D 3D TSV
3360396219Methionine Adenosyltransferase Inhibitors for the Treatment of Cancer.EBIACS Med Chem Lett 12: 180-181 (2021)Usona Institute2D 3D TSV
3360396333Potential of Cyclin-Dependent Kinase Inhibitors as Cancer Therapy.EBIACS Med Chem Lett 12: 182-184 (2021)Therachem Research Medilab, LLC2D 3D TSV
3360396557Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors.EBIACS Med Chem Lett 12: 195-201 (2021)Shanghai Hengrui Pharmaceutical Co., Ltd.2D 3D TSV
336039661Investigation on the Anticancer Activity of Symmetric and Unsymmetric Cyclic Sulfamides.EBIACS Med Chem Lett 12: 202-210 (2021)National Institutes of Health (NIH) National Center of Excellence for Computational Drug Abuse Research2D 3D TSV
3360396738Discovery of Carbono(di)thioates as Indoleamine 2,3-Dioxygenase 1 Inhibitors.EBIACS Med Chem Lett 12: 211-216 (2021)Kogakuin University2D 3D TSV
3360396834Virtual Screening Approach to Identifying a Novel and Tractable Series of EBIACS Med Chem Lett 12: 217-227 (2021)Antabio SAS2D 3D TSV
336039698Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer.EBIACS Med Chem Lett 12: 236-241 (2021)National Institute of Health Sciences2D 3D TSV
3360397012Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication.EBIACS Med Chem Lett 12: 242-248 (2021)Korea Research Institute of Chemical Technology2D 3D TSV
3360397119Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.EBIACS Med Chem Lett 12: 249-255 (2021)Yale University2D 3D TSV
3360397421A New FXR Ligand Chemotype with Agonist/Antagonist Switch.EBIACS Med Chem Lett 12: 267-274 (2021)Goethe-University Frankfurt2D 3D TSV
3360397761Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1.EBIACS Med Chem Lett 12: 288-294 (2021)Bristol Myers Squibb Research and Development2D 3D TSV
3360397944Fragment-Based Discovery of Novel Allosteric MEK1 Binders.EBIACS Med Chem Lett 12: 302-308 (2021)AstraZeneca2D 3D TSV
3373804761-Pyrazolyl-5,6-Disubstituted Indazole Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.EBIACS Med Chem Lett 12: 310-311 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
337380486Novel Oxazine Monoacylglycerol Lipase (MAGL) Inhibitors.EBIACS Med Chem Lett 12: 312-313 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
337380496Novel Benzimidazole Derivatives as Transient Receptor Potential Channel 6 (TRPC6) Inhibitors.EBIACS Med Chem Lett 12: 314-315 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
337380526Novel Bicyclic Heterocycles as FGFR Inhibitors for Treating Cancer.EBIACS Med Chem Lett 12: 320-321 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3373805510Tumor-Targeted Bivalent Protein Degradation for Application in Cancer Therapy.EBIACS Med Chem Lett 12: 326-327 (2021)Usona Institute2D 3D TSV
3373805610Targeting Stimulator of Interferon Genes (STING) for the Potential Treatment of Cancer and Infectious Diseases.EBIACS Med Chem Lett 12: 328-330 (2021)Usona Institute2D 3D TSV
3373805810Myeloid Cell Leukemia-1 Inhibitors as Emerging Cancer Treatment.EBIACS Med Chem Lett 12: 334-336 (2021)Therachem Research Medilab, LLC.2D 3D TSV
33738059144Synthesis of HDAC Inhibitor Libraries via Microscale Workflow.EBIACS Med Chem Lett 12: 337-342 (2021)Merck & Co.2D 3D TSV
3373806143Novel Potent Selective Orally Active S1P5 Receptor Antagonists.EBIACS Med Chem Lett 12: 351-355 (2021)Biogen Inc.2D 3D TSV
3373806399Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin.EBIACS Med Chem Lett 12: 365-372 (2021)University of Gda?sk2D 3D TSV
33738064156Biological Evaluation of 5'-(EBIACS Med Chem Lett 12: 373-379 (2021)National Institute of Diabetes and Digestive and Kidney Diseases2D 3D TSV
3373806578Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.EBIACS Med Chem Lett 12: 380-388 (2021)Charles River Discovery2D 3D TSV
3373806659Carbamate and EBIACS Med Chem Lett 12: 389-396 (2021)Merck & Co., Inc.2D 3D TSV
3373806771Discovery of 5-Benzylidene-2-phenyl-1,3-dioxane-4,6-diones as Highly Potent and Selective SIRT1 Inhibitors.EBIACS Med Chem Lett 12: 397-403 (2021)Chinese Academy of Sciences2D 3D TSV
3373807016Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum.EBIACS Med Chem Lett 12: 420-425 (2021)Hiroshima International University2D 3D TSV
3373241214The Basicity Makes the Difference: Improved Canavanine-Derived Inhibitors of the Proprotein Convertase Furin.EBIACS Med Chem Lett 12: 426-432 (2021)Philipps University2D 3D TSV
3373241385Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.EBIACS Med Chem Lett 12: 443-450 (2021)Bristol Myers Squibb Company2D 3D TSV
3373807293Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes.EBIACS Med Chem Lett 12: 451-458 (2021)Janssen Research & Development, LLC2D 3D TSV
3373807345Identification of Potent Reverse Indazole Inhibitors for HPK1.EBIACS Med Chem Lett 12: 459-466 (2021)Merck & Co.2D 3D TSV
3373807626Structure-based Discovery of Cell-Potent Peptidomimetic Inhibitors for Protein N-Terminal Methyltransferase 1.EBIACS Med Chem Lett 12: 485-493 (2021)Purdue University2D 3D TSV
3373807765Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.EBIACS Med Chem Lett 12: 494-501 (2021)Bristol Myers Squibb Research and Development2D 3D TSV
338597886Novel Pyridazines as Autotaxin Inhibitors for Treating Inflammatory Airway or Fibrotic Diseases.EBIACS Med Chem Lett 12: 528-529 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
338597896Novel N-Heteroaryl Indazole Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.EBIACS Med Chem Lett 12: 530-531 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
338597906Thienopyridinyl and Thiazolopyridinyl Compounds as IRAK4 Inhibitors.EBIACS Med Chem Lett 12: 532-533 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
338597934Novel Pyrimidine-5-carboxamide Compounds as NNMT Inhibitors for Treating Diabetes.EBIACS Med Chem Lett 12: 538-539 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3385979545Discovery of 2,4-1EBIACS Med Chem Lett 12: 555-562 (2021)ZoBio BV2D 3D TSV
338597975Discovery of a Highly Selective and Potent TRPC3 Inhibitor with High Metabolic Stability and Low Toxicity.EBIACS Med Chem Lett 12: 572-578 (2021)the University of Tennessee Health Science Center2D 3D TSV
3385980048Discovery of the First Orally Available, Selective KEBIACS Med Chem Lett 12: 593-602 (2021)Praxis Precision Medicines2D 3D TSV
3385470233Synthesis, Inhibitory Activity, and EBIACS Med Chem Lett 12: 610-616 (2021)Czech Academy of Sciences2D 3D TSV
338598015A Set of Highly Sensitive Sirtuin Fluorescence Probes for Screening Small-Molecular Sirtuin Defatty-Acylase Inhibitors.EBIACS Med Chem Lett 12: 617-624 (2021)Nagoya City University2D 3D TSV
3385470326Covalent Occlusion of the ROR?t Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.EBIACS Med Chem Lett 12: 631-639 (2021)Technische Universiteit Eindhoven2D 3D TSV
3385980349Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.EBIACS Med Chem Lett 12: 647-652 (2021)Jinan University2D 3D TSV
3405520514Pyrrolo-pyridazine Derivatives as Muscarinic MEBIACS Med Chem Lett 12: 677-678 (2021)Temple University School of Pharmacy2D 3D TSV
340552076Novel Substituted Exomethylene-oxindoles as HPK1 Inhibitors.EBIACS Med Chem Lett 12: 681-682 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
340552086Novel Pyrazolo[3,4-EBIACS Med Chem Lett 12: 683-684 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
340552116Novel Amide Compounds as KIF18A Inhibitors for Treating Cancer.EBIACS Med Chem Lett 12: 690-691 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
340552126Novel Heterobicyclic Carboxamides for Treating Eye Diseases.EBIACS Med Chem Lett 12: 692-693 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3405521413Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors.EBIACS Med Chem Lett 12: 696-703 (2021)Peking University Health Science Center2D 3D TSV
340552182Discovery of a Potent and Selective Covalent p300/CBP Inhibitor.EBIACS Med Chem Lett 12: 726-731 (2021)AbbVie, Inc.2D 3D TSV
3405522173Discovery of Selective Transforming Growth Factor ? Type II Receptor Inhibitors as Antifibrosis Agents.EBIACS Med Chem Lett 12: 745-751 (2021)Japan Tobacco Inc.2D 3D TSV
340552238Structural and in Vitro Functional Characterization of a Menthyl TRPM8 Antagonist Indicates Species-Dependent Regulation.EBIACS Med Chem Lett 12: 758-767 (2021)Marshall University2D 3D TSV
340552249Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists.EBIACS Med Chem Lett 12: 768-773 (2021)University of Groningen2D 3D TSV
3405522716Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor.EBIACS Med Chem Lett 12: 791-797 (2021)Genentech2D 3D TSV
3405522845Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells.EBIACS Med Chem Lett 12: 798-804 (2021)University of Alberta2D 3D TSV
3405523135Discovery of a Novel Class of ERR? Agonists.EBIACS Med Chem Lett 12: 817-821 (2021)Daiichi Sankyo Co., Ltd.2D 3D TSV
3405523392Azatricyclic Inverse Agonists of ROR?t That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.EBIACS Med Chem Lett 12: 827-835 (2021)Bristol Myers Squibb Company2D 3D TSV
3405523452Discovery of 1,5-Dihydro-4EBIACS Med Chem Lett 12: 836-845 (2021)Zhejiang University2D 3D TSV
341410552Novel Small Molecule RNA m6A Demethylase AlkBH5 Inhibitors for Treating Cancer.EBIACS Med Chem Lett 12: 856-857 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
341410766Benzo[d]thiazol-5-yl Compounds as O-GlcNAcase Inhibitors for Treating Alzheimer's Disease.EBIACS Med Chem Lett 12: 947-948 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3414107812Novel Bromodomain BRD4 Inhibitors for Treating Cancer.EBIACS Med Chem Lett 12: 951-952 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3414107965-Fluoronicotinamide Derivatives as HDAC6 Inhibitors for Treating Heart Diseases.EBIACS Med Chem Lett 12: 953-954 (2021)Smith, Gambrell & Russell LLP2D 3D TSV
3414108049Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors.EBIACS Med Chem Lett 12: 955-960 (2021)Vertex Pharmaceuticals Inc2D 3D TSV
3414108243Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.EBIACS Med Chem Lett 12: 969-975 (2021)Bristol Myers Squibb Company2D 3D TSV
341410849SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.EBIACS Med Chem Lett 12: 996-1004 (2021)University of Michigan2D 3D TSV
3414108557Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.EBIACS Med Chem Lett 12: 1005-1010 (2021)GlaxoSmithKline2D 3D TSV
3414108611Structure-Based Design of A-1293102, a Potent and Selective BCL-XEBIACS Med Chem Lett 12: 1011-1016 (2021)AbbVie Inc.2D 3D TSV
3414108711Discovery of Novel PTP1B Inhibitors Derived from the BH3 Domain of Proapoptotic Bcl-2 Proteins with Antidiabetic Potency.EBIACS Med Chem Lett 12: 1017-1023 (2021)Qingdao University of Science and Technology2D 3D TSV
341410886Creation of Fluorescent RXR Antagonists Based on CBTF-EE and Application to a Fluorescence Polarization Binding Assay.EBIACS Med Chem Lett 12: 1024-1029 (2021)Okayama University Graduate School of Medicine2D 3D TSV
3414109052Discovery of Arylsulfonamide NaEBIACS Med Chem Lett 12: 1038-1049 (2021)Merck & Co.2D 3D TSV
3440880840Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.BDBACS Med Chem Lett 12: 1325-1332 (2021)Yale University2D 3D TSV
3440880832Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral PotencyBDBACS Med Chem Lett 12: 1325-1332 (2021)Yale University2D 3D TSV